A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated

Trial Profile

A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Jan 2018

At a glance

  • Drugs Paliperidone (Primary) ; Aripiprazole; Haloperidol; Olanzapine; Paliperidone; Perphenazine; Quetiapine; Risperidone
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Acronyms PRIDE
  • Sponsors Janssen Pharmaceuticals
  • Most Recent Events

    • 03 Jan 2018 Results presented in a Johnson & Johnson Media Release.
    • 03 Jan 2018 According to a Janssen Pharmaceuticals media release, the U.S. FDA approved the inclusion of real-world data from this study in the INVEGA SUSTENNA label.
    • 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top